Who bought leap Therapeutics (LPTx)?
LPTX stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., BlackRock Inc., Citadel Advisors LLC, and McAdam LLC. View insider buying and selling activity for Leap Therapeutics or view top insider-selling stocks. Which institutional investors are buying Leap Therapeutics stock?
What are analysts'target prices for leap Therapeutics'stock?
4 equities research analysts have issued 12-month target prices for Leap Therapeutics' stock. Their forecasts range from $4.00 to $6.00. On average, they expect Leap Therapeutics' share price to reach $4.50 in the next twelve months.
What is the upside for leap Therapeutics'stock?
Their forecasts range from $4.00 to $6.00. On average, they expect Leap Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price.
What does leap Therapeutics do?
Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer.
See more
Is leap Therapeutics a buy?
Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is LPTX stock a buy?
The consensus among 2 Wall Street analysts covering (NASDAQ: LPTX) stock is to Strong Buy LPTX stock.
What does leap therapeutics do?
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, colorectal, gynecologic, and prostate cancers.
Should I buy or sell Leap Therapeutics stock right now?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently...
What is Leap Therapeutics' stock price forecast for 2022?
3 brokerages have issued 1 year price objectives for Leap Therapeutics' stock. Their forecasts range from $4.00 to $6.00. On average, they expect L...
How has Leap Therapeutics' stock performed in 2022?
Leap Therapeutics' stock was trading at $3.24 at the start of the year. Since then, LPTX stock has decreased by 67.0% and is now trading at $1.07....
When is Leap Therapeutics' next earnings date?
Leap Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Lea...
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics, Inc. (NASDAQ:LPTX) posted its earnings results on Friday, May, 13th. The company reported ($0.09) EPS for the quarter, topping t...
Who are Leap Therapeutics' key executives?
Leap Therapeutics' management team includes the following people: Mr. Douglas E. Onsi J.D. , CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Dir...
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include DiaMedica Therapeutics (DMCAF) , Intercept Pharmaceuticals (ICPT) , Kinnate Biophar...
What other stocks do shareholders of Leap Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuti...
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
About Leap Therapeutics
Headlines
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer.
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
How Many Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares Do Institutions Own?
What is leap therapeutics?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Leap Therapeutics stock. View analyst ratings for Leap Therapeutics or view top-rated stocks.
Does market cap include convertible securities?
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells.
